Protagonist Therapeutics, Inc. (PTGX)

NASDAQ:
PTGX
| Latest update: Mar 15, 2026, 8:00 PM

Price Chart

$92.36

3.21%
(1 month)

Top Shareholders

BlackRock, Inc.
15.54%
Farallon Capital Management LP
9.83%
The Vanguard Group, Inc.
8.67%
RTW Investments LP
8.09%
State Street Corp.
5.12%
Wellington Management Group LLP
5.07%
UBS Group AG
4.60%
Janus Henderson Group Plc
4.24%

Sentiment for PTGX

News
Social

Buzz Talk for PTGX

Today

Social Media

General

Stock events for Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics' stock price has seen significant movement in the past six months, with the stock price as of March 2, 2026, at $94.31 per share. Key events impacting the stock include the NDA submission and priority review for rusfertide, regulatory progress for icotrokinra, positive analyst ratings and price targets, potential opt-out of Takeda profit-sharing, Johnson & Johnson acquisition talks in October 2025, and the company's fourth quarter and full year 2025 financial results.

Demand Seasonality affecting Protagonist Therapeutics, Inc.’s stock price

Information regarding specific demand seasonality for Protagonist Therapeutics' products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue primarily comes from licensing and collaboration agreements rather than direct product sales. The demand for its investigational drugs would be driven by the prevalence of the diseases they aim to treat and the success of clinical trials and regulatory approvals, rather than seasonal fluctuations.

Overview of Protagonist Therapeutics, Inc.’s business

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutic drugs. They operate in the biotechnology industry, addressing unmet medical needs in hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's Peptide 2.0 platform designs peptides targeting G protein-coupled receptors and cytokine receptors, aiming for the potency of biologics with oral administration convenience. Key product candidates include rusfertide, an injectable hepcidin mimetic in Phase 3 for polycythemia vera (PV) with an NDA submitted in January 2026; icotrokinra, an orally delivered IL-23R specific antagonist in Phase 3 for inflammatory diseases with an NDA for plaque psoriasis submitted in July 2025; PN-881, a potential oral peptide IL-17 antagonist in Phase 1 for immune-mediated skin diseases; PN-477 and PN-458 for obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; and other programs including an L-4R alpha antagonist and amylinR-based agonists for obesity.

PTGX’s Geographic footprint

Protagonist Therapeutics has a global presence with innovation hubs in the U.S. and Australia. The corporate headquarters are in Newark, California, and the discovery research team is based in Brisbane, Australia. The company also conducts global clinical trials across North America, Europe, and Asia.

PTGX Corporate Image Assessment

Protagonist Therapeutics' brand reputation appears to be largely positive, driven by strong clinical data and regulatory progress for its pipeline products. The company has received robust analyst support, with a consensus "Buy" rating and increased price targets. Key events contributing to its positive reputation include positive clinical trial data, regulatory milestones, and strategic partnerships.

Ownership

Protagonist Therapeutics, Inc. is overwhelmingly controlled by institutional capital, which is common for publicly-traded, mid-cap biotechnology firms focused on late-stage clinical development. Major institutional owners and shareholders include BlackRock, Inc., Farallon Capital Management Llc, and Vanguard Group Inc. Individual ownership includes executives and directors such as CEO Dinesh V. Patel, Ph.D., and Chief Medical Officer Arturo Molina, M.D. Julie Papanek is noted as a significant individual shareholder, owning 3.84% of the company.

FAQ

What is the current stock price of Protagonist Therapeutics, Inc.?

As of the latest update, Protagonist Therapeutics, Inc.'s stock is trading at $92.36 per share.

What’s happening with Protagonist Therapeutics, Inc. stock today?

Today, Protagonist Therapeutics, Inc. stock is down by -3.21%, possibly due to news.

What is the market sentiment around Protagonist Therapeutics, Inc. stock?

Current sentiment around Protagonist Therapeutics, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Protagonist Therapeutics, Inc.'s stock price growing?

Over the past month, Protagonist Therapeutics, Inc.'s stock price has decreased by -3.21%.

How can I buy Protagonist Therapeutics, Inc. stock?

You can buy Protagonist Therapeutics, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol PTGX

Who are the major shareholders of Protagonist Therapeutics, Inc. stock?

Major shareholders of Protagonist Therapeutics, Inc. include institutions such as BlackRock, Inc. (15.54%), Farallon Capital Management LP (9.83%), The Vanguard Group, Inc. (8.67%) ... , according to the latest filings.